Notably, a single subcutaneous injection of the monoclonal PCSK9 antibody evolocumab reduced the need for intubation and/or mortality and lowered serum interleukin (IL)-6 in patients with severe COVID-19 [21]. This evidence concerns the gene PCSK9 and COVID-19.